What the NHS' new benchmark prices for ADHD and autism assessments actually mean
The NHS has announced benchmark prices it will pay for private ADHD assessments: £850 for face-to-face adult assessments, £700 for virtual assessments, and £950 for children. The framing from NHS England positions this as protecting patients and taxpayers from clinics charging up to £2,000 per diagnosis.
Dr Adrian James, the national director for neurodiversity (did you know that role existed? do you know what it has achieved, and what it does?), stated the surge in demand has created “unacceptable variation” in assessment costs. The new guidance, he said, is “an important first step in ensuring that ADHD assessments are on an equal footing.”
The numbers behind the announcement tell a different story. The NHS outsourced over 100,000 ADHD assessments to private providers last year. Spending from the NHS to private ADHD clinics reached an estimated £128 million — up from £36 million two years prior. Most assessments are now online, and more than 80% of referrals to some clinics result in an ADHD diagnosis.
That 80%+ figure is presented as evidence of overdiagnosis. Rogue clinics handing out diagnoses too freely. The implication: if the NHS caps what it pays and tightens guidelines, quality will improve and costs will stabilise.
But this framing assumes the problem is dodgy clinics, not systemic failure. It assumes private providers created the demand rather than responding to it. And it assumes price caps address the structural issues that pushed hundreds of thousands of people to private assessment in the first place.
None of those assumptions survive scrutiny.
£512 million in private spending and what FOI data reveals about accountability
Freedom of Information requests submitted to all 42 English Integrated Care Boards (The Neurodiversity Directory, 2026 FOI data) reveal the scale the NHS announcement doesn’t mention. NHS ICBs have spent at least £512 million on private ADHD and autism assessments since 2023/24. Private spending increased 131% year-on-year between 2023/24 and 2024/25. West Yorkshire ICB alone spent £17.6 million in a single year. Greater Manchester — while actively restricting Right to Choose referrals — projects £22.3 million for 2025/26.
The more revealing finding is what ICBs cannot report. Only 4 of 42 could provide data on how many assessments their private spending actually purchased. Only 4 could report average waiting times. Derby and Derbyshire — among the few tracking wait times — reported an average of 2,321 days from referral to assessment. That is 6.4 years.
This is the context the benchmark pricing announcement omits. The NHS is not overpaying rogue clinics because it lacks cost controls. It is haemorrhaging money to private providers because its own services collapsed and cannot fulfil its promises to its people (which is the REAL demand private clinics are filling), and it has no infrastructure to measure what that money buys, nor care to track the performance of treatment.
ICBs receive invoices. They pay invoices. Spending doubles year after year. But they cannot say with any accuracy how many people were assessed for what they are paying, how long those people waited, or what happened after diagnosis. The benchmark prices address the unit cost of assessments. They do not address the complete absence of outcome measurement, the years-long NHS waiting lists that drive private demand, or the structural incentives that make this situation profitable for everyone except patients.
Setting a price cap on a system you cannot measure is not cost control. It is the appearance of cost control. And all it reveals is that their top priority is not actually neurodivergent care but processing of invoices.
Why capping NHS prices shifts costs to patients rather than fixing access
Here is what happens when the NHS refuses to pay £2,000 for an assessment:
Private clinics operating through Right to Choose face a choice. Accept £700–950 from the NHS per assessment, or decline NHS-funded patients and charge individuals directly. Some will accept the lower rates to maintain volume. Others — particularly those with established reputations and full booking schedules — will simply stop taking Right to Choose referrals.
The demand does not disappear. The hundreds of thousands of people who sought private assessment last year did so because NHS waiting lists stretch years, not weeks. The benchmark prices do nothing to expand NHS capacity. They do nothing to reduce waiting times. They do nothing to address the fundamental mismatch between assessment demand and public service provision.
What they do is create price segmentation. NHS-funded assessments at £700–950 for those who can navigate Right to Choose while it still exists. Full private fees — £1,500, £2,000, or more — for everyone else.
The celebratory PR around charities (of all people) now charging £2,000 for ADHD assessments illustrated where this leads. When even charities enter the diagnostic market at premium prices, you are not witnessing a temporary market distortion. You are witnessing the institutionalisation of tiered access based on ability to pay.
The NHS benchmark prices accelerate this. By capping what it will fund, the NHS creates a floor for public provision and abandons everyone above it. Patients with means pay privately. Patients without means wait years. The “unacceptable variation” Dr James identified becomes acceptable variation — variation between those who can afford immediate access and those who cannot.
The two-tier ADHD assessment system benchmark pricing cements
The structure emerging for ADHD assessments in the UK is straightforward:
Tier one: NHS-funded assessment through Right to Choose, subject to benchmark pricing, available where ICBs still honour referrals. Eleven of 42 ICBs have already restricted or paused Right to Choose for ADHD and autism. The benchmark prices give remaining ICBs financial justification to follow. Why fund assessments at £850 when budgets are constrained and you can simply… not?
Tier two: Private assessment at market rates for anyone unwilling or unable to wait. Current waiting lists mean “unwilling to wait” includes anyone who needs support within the next several years. Market rates remain whatever clinics choose to charge, unconstrained by NHS benchmarks because they are not billing the NHS.
The gap between tiers widens as NHS provision contracts. Each ICB that restricts Right to Choose pushes more patients into tier two. Each budget pressure that delays NHS capacity expansion extends waiting times that make tier one functionally inaccessible. The benchmark prices do not bridge this gap. They institutionalise it.
Meanwhile, the diagnostic gatekeeping remains untouched. You still cannot access ADHD support — workplace support and accommodations, medication, educational adjustments — without formal diagnosis. Diagnosis still requires either years of waiting or thousands in private fees. The system still extracts payment from neurodivergent people for access to labels they need to function in neurotypical environments built without them in mind.
The NHS announcement presents benchmark pricing as reform. It is not reform. It is cost management within a broken system — a system that creates artificial scarcity, profits from diagnostic gatekeeping, and now offers tiered access based on wealth rather than need.
Eighty-two thousand people in England have ADHD diagnoses. Two hundred ninety-seven thousand are on medication. Hundreds of thousands more wait for assessment. The benchmark prices change what the NHS pays per invoice. They change nothing about why those invoices exist, why demand continues to surge, or why the people generating that demand cannot access timely public assessment.
The NHS has refused to continue processing invoices of £2,000+ for ADHD assessments, and are now dictating what THEY pay. So the cost does not disappear. It simply moves — from public budgets to patient pockets, from institutional responsibility (which they didn’t have anyway) to individual burden (which was already in place). That is not a solution to diagnostic gatekeeping. It is diagnostic gatekeeping with better PR.
Citations
The Neurodiversity Directory — NHS private spending on ADHD & autism by ICB (2026 FOI data)
The Neurodiversity Directory — Neurodiversity statistics and research
